Lack of Association between CYP1A1 M2 and M4 Polymorphisms and Breast Carcinoma in Jordanian Women: a Case-Control Study

  • Amrani, Iman (Department of Pharmacy, Faculty of Medicine, University of Batna Algeria) ;
  • Bulatova, Nailya (Department of Biopharmaceutics and Clinical Pharmacy. Faculty of Pharmacy, The University of Jordan) ;
  • Awidi, Abdalla (Department of Hematology and Oncology, The University of Jordan Hospital) ;
  • Yousef, Al-Motassem (Department of Biopharmaceutics and Clinical Pharmacy. Faculty of Pharmacy, The University of Jordan) ;
  • Melhem, Jamal Masad (Department of Surgery, The University of Jordan Hospital) ;
  • Al-Masri, Mahmoud (Department of Surgical Oncology, King Hussein Cancer Center) ;
  • Tahoun, Laila Abu (Department of Radiology, King Hussein Cancer Center)
  • Published : 2016.02.05


Background: CYP1A1 is a candidate gene for low-penetrance breast cancer susceptibility, as it plays an important role in the metabolism of carcinogens and estrogens. Purpose: The objective of this study was to assess the association between M2 (A2455G, Ile462Val) and M4 (C2453A, Thr461Asn) polymorphisms in CYP1A1 and breast cancer risk among Jordanian women and in subgroups stratified by menopausal status and smoking history. Materials and Methods: Blood samples were collected from 112 breast cancer female patients and 115 age-matched controls who underwent breast cancer screening with imaging and showed negative results (BI-RADS I or BI-RADS II). Genotyping was performed using the PCR-RFLP technique. Results: No statistically significant overall association was found between breast cancer risk and CYP1A1 M2 genotypes (p= 0.55; OR = 0.77; 95% CI= 0.32 - 1.83) nor with the M4 polymorphism (p= 0.95; OR= 0.95; 95% CI= 0.51 - 1.88). Analysis of subgroups defined by menopausal status or smoking history also revealed no association with these polymorphisms. Furthermore, the four identified haplotypes (AC; AA; GC and GA) were equally distributed among cases and controls, and haplotype analysis showed a strong linkage disequilibrium of both studied loci in either cases or controls (D'=1). Conclusions: Based on the study results, CYP1A1 M2 and M4 polymorphisms do not seem to play a major role in breast cancer risk among Jordanian females.


CYP1A1;breast cancer;genotype;genetic polymorphism;SNP;Jordanian women;menopause;smoking


  1. Ambrosone CB, Freudenheim JL, Graham S, et al (1995). Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res, 55, 3483-5.
  2. Bailey LR, Roodi N, Verrier CS, et al (1998). Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res, 58, 65-70.
  3. Basham VM, Pharoah PD, Healey CS, et al (2001). Polymorphisms in CYP1A1 and smoking: no association with breast cancer risk. Carcinogenesis, 22, 1797-800.
  4. Boyapati SM, Shu XO, Gao YT, et al (2005). Polymorphisms in CYP1A1 and breast carcinoma risk in a population-based case-control study of Chinese women. Cancer, 103, 2228-35.
  5. Cascorbi I, Brockmoller J, Roots I (1996). A C4887A polymorphism in exon 7 of human CYP1A1: Population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res, 56, 4965-69.
  6. Cavalieri N, Rogan E, Sinha D (1988). Carcinogenicity of aromatic hydrocarbons directly applied to rat mammary gland. J Cancer Res ClinOncol, 114, 3-9.
  7. Chacko P, Joseph T, Mathew BS, et al (2005). Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome. MutatRes, 581,153-63.
  8. Clemons M, Goss P (2001). Estrogen and the risk of breast cancer. N Engl J Med, 344, 276-85.
  9. Cosma G, Crofts F, Taioli E, et al (1993). Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health, 40, 309-16.
  10. Crofts F, Taioli E, Trachman J, et al (1994). Functional significance of different human CYP1A1 genotypes. Carcinogenesis, 15, 2961-3.
  11. Firozi PF, Bondy ML, Sahin AA, et al (2002). Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer. Carcinogenesis, 23, 301- 6.
  12. Giri SK, Yadav A, Kumar A, et al (2012). CYP1A1 gene polymorphisms: modulator of genetic damage in coal-tar workers. Asian Pac J Cancer Prev, 13, 3409-16.
  13. Hefler LA, Tempfer CB, Grimm C, et al (2004). Estrogenmetabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer, 101, 264-9.
  14. Henkler F, Stolpmann K, Luch A (2012). Exposure to polycyclic aromatic hydrocarbons: bulky DNA adducts and cellular responses. EXS, 101, 107-31.
  15. Hodek P, Koblihova J, Kizek R, et al (2013). The relationship between DNA adduct formation by benzo[a]pyrene and expression of its activation enzyme cytochrome P450 1A1 in rat. Environ Toxicol Pharmacol, 36, 989-96
  16. Huang CS, Shen CY, Chang KJ, et al (1999). Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan. Br J Cancer, 80, 1838-43.
  17. Huo D, Zheng Y, Ogundiran TO, et al (2012). Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis, 33, 835-40
  18. Ishibe N, Hankinson SE, Colditz GA, et al (1998). Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the nurses' health study. Cancer Res, 58, 667-71.
  19. Kawajiri K, Watanabe J, Gotoh O, et al (1986). Structure and drug inducibility of the human cytochrome P-450c gene. Eur J Biochem, 159, 219-25.
  20. Kiruthiga PV, Kannan MR, Saraswathi C, et al (2011). CYP1A1 gene polymorphisms: lack of association with breast cancer susceptibility in the southern region (Madurai) of India. Asian Pac J Cancer Prev, 12, 2133-8.
  21. Kiyohara C, Hirohata T, Inutsuka S (1996). The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res, 87, 18-24.
  22. Krajinovic M, Ghadirian P, Richer C, et al (2001). Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions. Int J Cancer, 92, 220-5.<::AID-IJC1184>3.0.CO;2-H
  23. Le Marchand L, Donlon T, Kolonel L, et al (2005). Estrogen Metabolism-related Genes and Breast Cancer Risk: the Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev, 14, 1998-2003.
  24. Li Y, Millikan R, Bell D, et al (2004). Cigarette smoking, cytochrome P4501A1 polymorphisms, and breast cancer among African-American and white women. Breast Cancer Res, 6, 460-73.
  25. Martinez-Ramirez OC, Perez-Morales R, Castro C, et al (2013). Polymorphisms of catechol estrogens metabolism pathway genes and breast cancer risk in Mexican women. Breast, 22, 335-43.
  26. Miyoshi Y, Takahashi Y, Egawa C, Noguchi S (2002). Breast cancer risk associated with CYP1A1 genetic polymorphisms in Japanese women. Breast J, 8, 209-15.
  27. Mrozikiewicz PM, Cascorbi I, Brockmoller J, Roots I (1997). CYP1A1 mutations 4887A, 4889G, 5639C and 6235C in the Polish population and their allelic linkage, determined by peptide nucleic acid-mediated PCR clamping. Pharmacogenetics, 7, 303-7.
  28. Persson I, Johansson I, Ingelman-Sundberg M (1997). In vitro kinetics of two human CYP1A1 variant enzymes suggested tobe associated with interindividual differences in cancer susceptibility. Biochem Biophys Res Commun, 231, 227- 30.
  29. Petchkovskiy EV, Shadrina AS, Boyarskih UA, et al (2014). The polymorphism of genes of synthesis and metabolism of estrogens and the risk of breast cancer. Klin Lab Diagn, 2, 19-23.
  30. Rebbeck TR, Rosvold EA, Duggan DJ, et al (1994). Genetics of CYP1A1: coamplification of specific alleles by polymerase chain reaction and association with breast cancer. Cancer Epidemiol Biomarkers Prev, 3, 511-4.
  31. Reding KW, Chen C, Lowe K, et al (2012). Estrogen-related genes and their contribution to racial differences in breast cancer risk. Cancer Causes Control, 23, 671-81.
  32. Saadatian H, Gharesouran J, Montazeri V, et al (2014). Polymorphism of the cytochrome P-450 1A1 (A2455G) in women with breast cancer in Eastern Azerbaijan, Iran. Iran J Basic Med Sci, 17, 227-30.
  33. Sergentanis T, Economopoulos K (2009). Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis. Breast Cancer ResTreat, 122, 459-69.
  34. Shimada T, Fujii-Kuriyama Y (2004). Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci, 95, 1-6.
  35. Shin A, Kang D, Choi JY, et al (2007). Cytochrome P450 1A1 (CYP1A1) polymorphisms and breast cancer risk in Korean women. ExpMol Med, 39, 361-6.
  36. Sillanpaa P. Heikinheimo L, Kataja V, et al (2007). CYP1A1 and CYP1B1 genetic polymorphisms, smoking and breast cancer risk in a Finnish Caucasian population. Breast Cancer Res Treat, 104, 287-97.
  37. Singh V, Rastogi N, Sinha A, et al (2007). A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women. Breast Cancer Res Treat, 101, 73-81.
  38. Spink DC, Eugster HP, Lincoln DW, et al (1992). $17{\beta}$-Estradiol hydroxylation catalyzed by human cytochrome P450 1A1: a comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. Arch Biochem. Biophys, 293, 342-8.
  39. Stuckey B (2011). Breast Cancer: Epidemiology and Risk Factors. Clin ObstetGynecol, 54, 96-102.
  40. Sun MY, Du HY, Zhu AN (2015). Genetic Polymorphisms in Estrogen-Related Genes and the Risk of Breast Cancer among Han Chinese Women. Int J Mol Sci, 16, 4121-35.
  41. Surekha D, Sailaja K, Rao D, et al (2009). Association of CYP1A1*2 polymorphisms with breast cancer risk: a case control study. Indian J Med Sci, 63, 13-20.
  42. Tarawneh M, Nimri O, Arkoob K, Al Zaghal M (2010). Cancer incidence in jordan 2010. the hashemite kingdom of jordan, ministry of health, non-communicable diseases directorate, jordan cancer registry. [online].
  43. Tsuchiya Y, Nakajima M, Yokoi T (2005). Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett, 227, 115-24.
  44. Tworoger SS, Zhang X, Eliassen AH, et al (2014). Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer. J Clin Oncol, 32, 3111-7
  45. Weber BL, Nathanson KL (2000). Low penetrance genes associated with increased risk for breast cancer. Eur J Cancer, 36, 1193-9.
  46. Zhang B, Beeghly-Fadiel A, Long J, et al (2011). Genetic variants associated with breast cancer risk: comprehensive field synopsis, meta-analysis, and epidemiologic evidence. Lancet Oncol, 12, 477-88.
  47. Zhang Y, Wise JP, Holford TR, et al (2004). Serum polychlorinatedbiphenyls, cytochrome P-450 1A1polymorphisms, and risk of breast cancer in Connecticut women. Am J Epidemiol, 160, 1177-83.
  48. Zhang Z, Fasco M, Huang L, et al (1996). Characterization of purified human recombinant cytochrome P4501A1-Ile462 and -Val462: assessment of a role for the rare allele in carcinogenesis. Cancer Res, 56, 3926-33.
  49. Zhu BT, Conney AH (1998). Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res, 58, 2269-77.